Partner logo here DEMENTIA RESEARCH Collaborative partnerships Translating evidence Research...
-
Upload
prosper-allen-reeves -
Category
Documents
-
view
216 -
download
0
Transcript of Partner logo here DEMENTIA RESEARCH Collaborative partnerships Translating evidence Research...
Partner logo here
DEMENTIA RESEARCHDEMENTIA RESEARCH
Collaborative partnerships • Translating evidence • Research partnerships
Translating dementia research into practice
Dementia research update
Professor Henry BrodatyDirector
Dementia Collaborative Research Centre – Assessment and Better Care
© DCRC/Brodaty 2012
Partner logo here
What’s new in What’s new in diagnosis?diagnosis?
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo herePartner logo here
Developments in diagnosisDevelopments in diagnosis
• New diagnostic criteria for DSM-V– “Major Neurocognitive Disorder”– Perminder Sachdev
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo herePartner logo here
New diagnostic criteria New diagnostic criteria 1. Preclinical AD: Earliest signs of disease,
before symptoms are noticed– Measurable changes in biomarkers
2. MCI due to AD: Mild changes to memory & thinking abilities
– Measurable but do not affect everyday activities
3. Dementia due to AD: Memory & thinking changes that impact daily life
Albert et al, Alzheimer’s & Dementia. 2011; 7(3): 270-279; Dubois et al, Lancet Neurol. 2010; 9:1118-1127; McKhann et al, Alzheimer’s & Dementia. 2011; 7(3): 263-269; Sperling et al, Alzheimer’s & Dementia. 2011; 7(3): 280-292.
Partner logo here
Advances in biomarkersAdvances in biomarkers• Cerebrospinal fluid
– Amyloid Protein (A) – Tau Protein (t and p)
• MRI scans – serial, fMRI• SPECT scans + dopamine label• PET Scans + amyloid ligands
– PiB and florbetapir Scans from the - online newspaper of Prof Yasser Metwally http://yassermetwally.wordpress.com/dementia-alzheimer-type-and-others/neuroimaging-of-dementia/
Healthy
MCI
AD
Healthy
Partner logo herePartner logo here
Translating dementia research into practice © DCRC/Brodaty 2012
Progressively increasing cerebral amyloid burden disclosed by Pittsburgh Imaging Compoud B (PiB) positron emission tomohraphywith increasing APOE ε4 gene dose in asymptomatic individuals age 50–69 years old, and in patients with probable Alzheimer’s disease.
Caselli & Reiman. J Alz Dis. DOI 10.3233/JAD-2012-129026
Partner logo herePartner logo here
Consequences of biomarkersConsequences of biomarkers
• Presymptomatic diagnosis• Alzheimer’s disease without dementia!• Issues – Conceptual – what is disease
– Ethical – Dx without Rx– Technical – reliability of tests– Cost– Availability - rural, dev. world
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo herePartner logo here
Definition of diseaseDefinition of disease
• What is AD?• Can there be Pre-symptomatic AD?• “A disease is any disturbance or anomaly
in the normal functioning of the body that probably has a specific cause and identifiable symptoms”
Translating dementia research into practice © DCRC/Brodaty 2011
http://www.ict-science-to-society.org/Pathogenomics/disease.htm
Partner logo herePartner logo here
Multiple pathologiesMultiple pathologies
• 20-30% of people with brain pathology of AD at post-mortem did not have dementia in life
• 75% of dementia occur in people aged 75+ • With older age correlation between AD
pathology and clinical symptoms decreases as vascular and other pathologies increase
• In Honolulu Asian Ageing Study best correlate with dementia was micro-infarcts not plaques
Translating dementia research into practice © DCRC/Brodaty 2011
Partner logo herePartner logo here
Dementia is a dimensional disease, on which Dementia is a dimensional disease, on which we apply categorical distinctionswe apply categorical distinctions
• Similarly apply cut-offs for pathology – eg number of
plaques at autopsy or on PiB imaging
Translating dementia research into practice © DCRC/Brodaty 2011
Procrustes at work
Partner logo herePartner logo here
Which combination of biomarkers best Which combination of biomarkers best predicts dementia?predicts dementia?
• Which aMCI are most likely to convert to AD?• What value is added by biomarkers over a selection
strategy based on cognition + genotype?
Strategy: 2 yr follow-up, sample from ADNI• aMCI converters (n = 25) vs. stable (n = 38)
Translating dementia research into practice © DCRC/Brodaty 2012
Yu et al 2012 J Alz Dis DOI 10.3233/JAD-2012-120832
Which combination of biomarkers best predicts dementia?
Yu et al 2012 J Alz Dis DOI 10.3233/JAD-2012-120832
Accuracy in aMCI for biomarker combinations in addition to ApoE genotype, ADAS-Cog & MMSE (= ‘none’) predicting AD within 2 years
Partner logo herePartner logo here
Which combination of biomarkers best Which combination of biomarkers best predicts dementia?predicts dementia?
• Most of increased power of tests due to MRI • FDG-PET & CSF incremental benefits• Considering time and costs
Translating dementia research into practice © DCRC/Brodaty 2012
Yu et al 2012 J Alz Dis DOI 10.3233/JAD-2012-120832
Combination Se Sp Costs Time
ApoE, ADAS-Cog, MMSE 52 68 -26% 1.85yr
MRI, ApoE, ADAS-Cog, MMSE 76 79 -26% 0.63yr
MRI, FDG-PET, CSF , ApoE, ADAS-Cog, MMSE
81 80 +19% 0.47yr
Partner logo herePartner logo here
Preclinical AD & pre-symptomatic interventionPreclinical AD & pre-symptomatic intervention
• Interventions after cognitive symptoms develop may be too late
• Distinguish preclinical AD from normal ageing– Genetic factors– Neuropathology– Imaging– CSF– Neuropsychology
Translating dementia research into practice © DCRC/Brodaty 2012
Caselli & Reiman. J Alz Dis. DOI 10.3233/JAD-2012-129026
Is amyloid hypothesis Is amyloid hypothesis still tenable?still tenable?
Translating dementia research into practice© DCRC/Brodaty 2012
Partner logo here
16
CSF Aβ42
Amyloid imaging
FDG-PET
MRI hipp
CSF tau
Cog
Function
Partner logo herePartner logo here
Protective mutationProtective mutation
• 0.5% of people in Iceland have a protective gene that prevents cognitive decline in old age 5x > likely to reach 85 with no AD
• Mutation reduces ability of enzyme (BACE) to break APP into smaller amyloid-β chunks
Translating dementia research into practice © DCRC/Brodaty 2012
Jonsson et al. 2012: doi:10.1038/nature11283
Partner logo here
© DCRC/Brodaty 2012
Aβ Deposition in Autosomal Dominant AD yrs before expected clinical symptoms
Carriers
Noncarriers
- 20y - 10y 0 yEstimated yrs from Sx onset
Bateman et al. N Engl J Med 2012; 367:795-804
Partner logo herePartner logo here
DIAN study – appearance before DIAN study – appearance before expected symptom onsetexpected symptom onset
• -25 years: CSF Aβ42 • -15 years: Aβ deposition detected by PiB PET• -15 yrs: CSF tau protein & brain atrophy• -10 y: cerebral metabolism; episodic memory• - 5 yrs: global cognition (MMSE, CDR)• 0 – estimated symptom onset• + 3 yrs: criteria for dementia met 3 years after SxBateman et al, 2012
© DCRC/Brodaty 2012
Partner logo here
What’s new in drug What’s new in drug treatment of treatment of
Alzheimer’s disease?Alzheimer’s disease?
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo herePartner logo here
Amyloid Amyloid plaqueplaque
Partner logo herePartner logo here
Tangles – tau proteinTangles – tau protein
Partner logo hereProteolytic Processing of APP Gives Rise to Proteolytic Processing of APP Gives Rise to
CP1217358-1
sAPPsAPP
C83C83
sAPPsAPP
AICDAICD
sAPPsAPP
Courtesy of Ron Petersen
Partner logo hereBest target for disease-modifying drug?Best target for disease-modifying drug?
-secretase inhibitor?
-secretase inhibitor?
•A oligomer?
•Aggregated fibrillar A ?
•A clearance mechanism?
•APP/ A processing?
Slide courtesy of Colin Masters
Partner logo herePartner logo hereSome failed strategiesSome failed strategies• Block -secretase: semagecestat X• Block amyloid aggregation: Alzhemed X• Selective Amyloid Lowering Agent: Tarenflurbil X• Mitochondria: Dimebon X• Immunotherapy: bapineuzemab X solanezumab X
ponezumab Abandoned• Leutinising hormone antagonist: Leuprolide X• Rosiglitazone X, Statins X, Anti-inflammatories X
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo hereSemagacestat Semagacestat
(gamma secretase inhibitor)(gamma secretase inhibitor) Phase III trial (“IDENTITY”)
Active arm deteriorated more rapidly Toxicity
Rash, skin cancers Hair whitening Diarrhoea
Partner logo herePartner logo here
Strategies under trialStrategies under trialBlock β-secretase: Merck
Immunotherapy: Gantenerumab
- Intravenous Gamma Globulin (IVIG)
Intranasal insulin
Metal ions: PBT2
Tau: Rember
234 intervention trials now recruiting www.clinicaltrials.gov.au (22.09.2012)
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo herePartner logo here
Patents expirePatents expire
• Galantamine • Memantine • Donepezil March 2013 • Rivastigmine (patch few years)
• Generics come on market, costs decrease
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo here
Non-pharmacological Non-pharmacological treatmenttreatment
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo herePartner logo here
Physical activity = protectivePhysical activity = protective• Several studies show physical
activity protective against cognitive decline, dementia, Alzheimer’s, vascular dementia
• More is better – puffed, weights
• At least 3x per week; > 150 mins/wk
• Check with your doctor1Jedrziewski et al (2007). Alz Dem; 3:98-108; 2 Lautenschlager et al (2008) JAMA; 300(9):1027-1037; 3Ravaglia et al (2007) Neurology; 4Larson et al (2006) Ann Intern Med; 144:73-81; 5Laurin et al, Arch Neurol 2001;58:498-504; 6Middelton et al, PLos ONE 2008;3(9):e3124
Partner logo here
Aerobic exerciseAerobic exercise• Meta-analysis of RCTs: aerobic exercise
training improves attention, processing speed, executive function & memory; effects on working memory less consistent
Smith et al. Psychosomatic Medicine 2010;72:(3) 239e252.
Partner logo herePartner logo here
Physical exercise & cognitive trainingPhysical exercise & cognitive training
• Physical exercise interventions– Improvements to cognition were associated
with biomarkers• Increased hippocampal blood flow• Increased levels cortisol, insulin, BDNF
• Cognitive training also showed assocn between cognition & neuroplasticity biomarkers
Translating dementia research into practice © DCRC/Brodaty 2012
Amoyal & Fallon Topics in Geriatric Rehabilitation 2012;28(3,): 208–216.
Partner logo here
-1
-0.5
0
0.5
1
1.5
6 mths 12 mths 18 mths
mea
n di
ffere
nce
on A
DAS
-Cog
fr
om b
asel
ine exercise group
control group
Improvement
Decline
Exercise
© DCRC/Brodaty 2010Lautenschlager et al (2008) JAMA; 300(9):1027-1037
N =138 memory complainers
Partner logo here
The power of physical activityThe power of physical activity
Erickson et al., 2011
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo here
Mind your brain: Mind your brain: Accumulating evidence Accumulating evidence
for mental exercise/ for mental exercise/ cognitive trainingcognitive training
Partner logo herePartner logo here
Mental Activity & Dementia Mental Activity & Dementia 1,21,2
• Meta-analysis of 22 studies, 29,000 people• Lifetime: Education, occupation, IQ, leisure
each reduce risk by about half• Late life: ↑ complex mental activity ↓ risk of
dementia by half
• Dose - response relationship evident• Complex patterns of mental activity in early,
mid- and late-life associated with ↓ dementia
1Valenzuela MJ. Sachdev P. (2006). Psychol Med. 36(4): 441-454; 2Valenzuela MJ. Sachdev P. (2006) Psychol Med. 36(8): 1065-1073
Partner logo herePartner logo here
Cognitive interventions healthy older Cognitive interventions healthy older adults & people with MCIadults & people with MCI
• Systematic review articles 2007-2012; 27 RCTs, 8 clinical studies. Cognitive training
• Majority - memory was outcome measure• 21 RCTs w healthy adults - memory improved in 17/20• 6 RCTs with MCI - memory improved in 4/6• Do improvements generalise to everyday activities??• Benefits preserved for 1-4 months; longer ??
Translating dementia research into practice © DCRC/Brodaty 2012
Reijnders, J., et al., Ageing Res. Rev. (2012), doi 10.1016/j.arr.2012.07.003
Partner logo herePartner logo here
Work & hippocampal atrophyWork & hippocampal atrophy
• 151 cognitively intact; mean age 80.8yrs• Follow-up over 2-3 years• Supervisory work in mid-life associated with
5x slower hippocampal atrophy in late-life• Not age, sex, Px activity, Apoε4, depressn
• Suggests link between mid-life cognitive lifestyle & long-term neuroplasticity
Translating dementia research into practice © DCRC/Brodaty 2012
Suo et al NeuroImage 2012; 63: 1542-1551.
Partner logo herePartner logo here
Cognitive stimulation for dementiaCognitive stimulation for dementia• Cognitive stimulation
– Activities for PWD eg reality orientation • Meta-analysis (n = 718; 15 RCT)• Benefit to cognition ES 0.41 (95% CI 0.25-0.57)
– 377 intervention/ 281 control; 15 studies• Benefit to communication & social interest
– ES 0.44 (0.17-0.71); 132/91; 4 studies • Also self rated well being & QoL
© DCRC/Brodaty 2012Aguirre, E., et al., Ageing Res. Rev. (2012), doi10.1016/j.arr.2012.07.001
Partner logo here
Cognitive training in ADCognitive training in AD• RCTs of multidomain CT in AD have
demonstrated positive effects on global cognitive measures and functional measures
Gates N, Valenzuela M. Current Psychiatry Reports 2010; 12:20-27
Partner logo herePartner logo here
Study of Mental & Regular Training (SMART)Study of Mental & Regular Training (SMART)
• Aim: Does increased mental activity lead to decreased dementia risk?
• Intervention: 3 days/wk for 6 months– Memory series + stretching/callisthenics– Memory series + strength exercise – Memory & thinking exercises +
stretching/callisthenics – Memory & thinking exercises + strength
• Follow up after 1 year to test for lasting benefits
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo here
Sleep, meditationSleep, meditation• Sleep – night (& daytime naps) enhance
memory, creativity• Meditation training: meta-analysis
– medium to large effect sizes for changes in emotionality and relationship issues
– medium effect sizes for attention– smaller effects on memory and several other
cognitive capacities (Sedlmeier et al., in press)
Dresler M et al, 2013 Neuropharmacology
Partner logo here
tDCStDCS
• Transcranial direct current stimulation (tDCS)– 1-2 mAmps, safe– Correct polarity and placement– Enhance memory and learning– Especially combined with cognitive training
• Trial for MCI in 2013 at CHeBA– Mohan, Martin, Loo, Brodaty, Sachdev
Partner logo here
PreventionPrevention
Partner logo herePartner logo here
Environment and ADEnvironment and AD
• Up to 50% of population attributable risk of AD cases from 7 environmental factors
• If 25% lower prevalence of these risk factors 3 million fewer AD cases worldwide
Translating dementia research into practice © DCRC/Brodaty 2012
Barnes D & Yaffe K, 2011
Partner logo herePartner logo here
How much AD can be attributed to How much AD can be attributed to environmental factors?environmental factors?
• 2% diabetes mellitus (type 2)• 2% midlife obesity*• 5% midlife hypertension• 10% depression• 13% physical inactivity*• 14% smoking• 19% cognitive inactivity/education#
Translating dementia research into practice © DCRC/Brodaty 2012
Barnes D & Yaffe K, 2011
Dementia risk reduction signposts
MIND your DIET
MIND your BODY
MIND your BRAIN
MIND your HEALTH CHECKS
MIND your SOCIAL LIFE
MIND your HEADMIND your HABITS
Partner logo here
Translating dementia research into practice
Study 1: • > adherence to Mediterranean
diet dementia risk ↓• “Dose” dependent effect Study 2: • N= 2364 Ss, FU 4.5 yrs• 275 incidents of MCI• Effects on incident MCI and
progression from MCI to AD
Scarmeas et al, Arch Neurol. 2006;59:912-921 Scarmeas et al, Arch Neurol. 2009;66(2)216-225
Mediterranean Diet to Prevent MCI & ADMediterranean Diet to Prevent MCI & AD
Partner logo herePartner logo here
Mediterranean diet & cognitionMediterranean diet & cognition
• Prospective cohort study N = 1410• Med diet assoc with fewer MMSE errors• Not associated with
– Incident dementia– Other cognitive tests (IST, BVRT, FCSRT)
Translating dementia research into practice © DCRC/Brodaty 2012
Feart et al. JAMA. 2009;302(6):638-648
Partner logo herePartner logo here
Mediterranean DietMediterranean Diet
• PATH Through Life study• N = 1528 (60-64 yrs); Follow-up 5yrs• 10 MCI, 19 CDR=0.5, 1491 healthy• 37 transitioned to any impairment at f/up• Med diet not protective against cognitive decline• Fish intake was protective for non clinical group
Translating dementia research into practice © DCRC/Brodaty 2012
Cherbuin & Anstey. Am J Geriatr Psychiatry 2012 20:7, 635-639.
Partner logo herePartner logo here
Fruit & vegetablesFruit & vegetables
• Cohort studies, 6months +• 9 studies, N = 44,004• Increased vegetable intake associated
with lower dementia risk & slower rates of cognitive decline
• Evidence for fruit intake is lacking
Translating dementia research into practice © DCRC/Brodaty 2012
Loef & Walch. J Nutrition, Health & Aging. 2012 ; 16(7): 626-630.
Partner logo here
BPSDBPSD
Partner logo herePartner logo here
Pharmacological interventions apathyPharmacological interventions apathy
• Review of pharmacological interventions– NHMRC Levels of Evidence (I-IV)
• Drugs reviewed:– Cholinesterase inhibitors– Memantine – Antipsychotics– Antidepressants– Stimulants– Other
Translating dementia research into practice © DCRC/Brodaty 2012
Berman K et al. Am J Ger Psychiatry Epub Aug 11 2011, doi:10.1097/JGP.0b013e31822001a6
Partner logo herePartner logo here
Pharmacological interventions apathyPharmacological interventions apathy
• Cholinesterase – supportive for their use• Memantine – limited evidence• Antipsychotics – no sound evidence for benefits in
general. Some evidence that atypical antipsychotics may help but ??? dependent on psychosis– Risks of stroke and death in dementia
• Antidepressants – good evidence they are not effective
Translating dementia research into practice © DCRC/Brodaty 2012
Berman K et al. Am J Ger Psychiatry Epub Aug 11 2011, doi:10.1097/JGP.0b013e31822001a6
Partner logo herePartner logo here
Non pharm interventions for apathyNon pharm interventions for apathy
• Therapeutic activities – has the best evidence for effectiveness
• Music therapies – some evidence, no RCTs• Exercise – RCT no sig effect• Multi-sensory – RCT no sig effect• Animal therapies – some positive trials
Translating dementia research into practice © DCRC/Brodaty 2012
Brodaty H & Burns K. Am J Geriatr Epub Aug 19 2011, doi:10.1097/JGP.0b013e31822be242
Partner logo herePartner logo here
CG interventions for BPSD in communityCG interventions for BPSD in community
• Reviewed effectiveness of community based psychosocial interventions
• 23 RCT or pseudo-randomised• Effective at reducing BPSD
– ES 0.34 (95% CI=0.20–0.48, p < .01)• Improved CG reactions to symptoms
– ES 0.15 (95% CI=0.04–0.26, p = .006)
Brodaty H & Arasaratnam C Am J Psychiatry 2012;169:946-953
Partner logo herePartner logo here
The Sydney Multisite Intervention of The Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE)LaughterBosses and ElderClowns (SMILE)
• Significant decrease in agitation in humour group vs controls at post and follow-up
• Depression and quality of life improved if allow for dose of intervention, commitment of Laughterbosses and Management support
• Key is resident engagement resident engagement which is facilitated by Laughterbosses & Management
Translating dementia research into practice © DCRC/Brodaty 2011
Partner logo herePartner logo here
Clinically significant?Clinically significant?
• 20% reduction in agitation symptoms in SMILE• The same effect size as is achieved by
antipsychotic medications used to treat agitation
OR
Partner logo herePartner logo here
Antipsychotics and dementiaAntipsychotics and dementia• Antipsychotics only partially successful at reducing
agitation & other behavioural problems• Increase risk of stroke and death• 180,000 PWD (UK) treated with antipsychotics
– 36,000 derive some benefit– 1800 might die– 1620 might suffer cerebrovascular event
Translating dementia research into practice © DCRC/Brodaty 2012
Banerjee 2009. The use of antipsychotic medication for people with dementia
Partner logo herePartner logo here
Analgesics and BPSD Analgesics and BPSD
• Cluster RCT; N = 352 RACF residents; mod-severe dementia; clinically sig behavioural disturbances
• Stepwise protocol for Rx pain (8wks) vs. usual Rx• Intervention: individual Rx of pain w. paracetamol
(70% of residents), buprenorphine transdermal patch, morphine or pregabaline
• Primary outcome: agitation (CMAI)
Translating dementia research into practice © DCRC/Brodaty 2012
Husebo et al. BMJ. 2011; 343: d4065.
Partner logo herePartner logo here
Translating dementia research into practice © DCRC/Brodaty 2012
Cohen-Mansfield agitation inventory scores, with 95% confidence intervals, over study period
Husebo et al. BMJ. 2011; 343: d4065.
Partner logo herePartner logo here
Dementia time to deathDementia time to death• The impact of dying decreased with age• Survival times varied (1.1- 8.5 yrs• longest max survival = AD
• Absolute loss of life was greatest for women, patients with YOD, FTD, DLB, young-onset AD, & mod/severe dementia
• Patients w. YOD, VaD, FTD & severe dementia lost at least 50% of remaining life expectancy
Brodaty H, Seeher K, Gibson L Int Psychog, 24:7, 1034-1045
Partner logo herePartner logo here
Sydney Centenarian StudySydney Centenarian Study
• Currently 3154 centenarians in Australia• Fastest growing age group world wide
– Models of ‘successful ageing’• Aims: better understand physical & mental
health of this group– Which factors contribute to longevity?
• 274 people aged 95+ recruited
Translating dementia research into practice © DCRC/Brodaty 2012
Sachdev P et al., 2012 Under review
Partner logo herePartner logo here
Sydney Centenarian StudySydney Centenarian Study
• 95-106 years old; 41 were 100+ years old• 28% men; 55% lived in private home• 87% impaired on ADLs• 72% satisfied with their general health• Cognitively and functionally impaired, yet the
exceptionally old demonstrate ability to view life with satisfaction and majority continue to live independently in the community
Translating dementia research into practice © DCRC/Brodaty 2012
Partner logo here
Translating dementia research into practice © DCRC/Brodaty 2012
Diagnosis of Dementia in a Centenarian Cohort N=274Cases with complete data
Cases above or below dementia cut-off
N n %MMSE 255 136 53ADL 185 155 83BADL 156 68 43CDR 110 61 55IQCODE 104 53 51Previous diagnosis of dementia 123 28 22
MMSE and ADL 171 94 55MMSE and BADL 146 38 26MMSE and CDR 96 43 44
(MMSE or ADL) and previous diagnosis of dementia 122 19 15(MMSE or BADL) and previous diagnosis of dementia 119 16 13
(MMSE or CDR) and previous diagnosis of dementia 121 15 12
(MMSE and ADL) or previous diagnosis of dementia 109 76 69(MMSE and BADL) or previous diagnosis of dementia 98 44 45
(MMSE and CDR) or previous diagnosis of dementia 65 35 53
Rate of dementia =12 – 83%
If exclude need for previous formal Dx and 1 outlier, rate of dementia = 26 –55%
Overall, median 50% have dementia
Partner logo here
• Wave 1: 36.1% (99/274)
• Wave 2: 31.1% (28/90)
• Impaired cognition defined as MMSE < 24, or if test missing because person judged too cognitively impaired to do the test
• Impaired function classification was based on 4 impairment variables:– ADL > 12– B-ADL ≥ 3– CDR 4 (household tasks) >3– IQCODE > 3.31
Impaired if >2 of above
DementiaDementia
Partner logo hereThank you and Megan HeffernanThank you and Megan Heffernan
www.dementiaresearch.org.au
Jeanne Calment
1875-1997